

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

The PIM planners and Dysautonomia International planners have nothing to disclose.

Dr. Brent Goodman, Dr. Blair Grubb, Dr. Russell Norris, Dr. Howard Snapper, Dr. Tae Hwan Chung, Dr. Courtney Gensemer, have nothing to disclose.

Dr. Joshua Wechsler has to disclose. Consulting fees from Regeneron/Sanofi, Astrazenea, CellDex, Ellodi, Allakos, BMS Grant funding from Regeneron/Sanofi

Dr. Svetlana Blitshtyen has to disclose. Consulting fees from CSL Behring. D

r. Peter Novak has to disclose. Consulting fees from Advisor - independent Contractor for Dysimmune Diseases Foundation. Grant funding from Mona Taliaferro/Bay Shore Recycling, The National Heart, Lung and Blood Institute (NHLNI- 1OT2HL156812-01), FBRI (2022A018462)

Dr. Kamal Chémali has to disclose. Consulting fees from CSL Behring. Grant funding from NIH, Sjogren's Foundation, Dysautonomia International.

Dr. Satish Raj has to disclose. Consulting fees from Novo Nordisk, Lumia Health, Antag Pharma, Argenx, Regeneron.

Dr. Xiaolong Peng discloses grant funds from NIH/NIDA 1RM1NS128787 Bob Sammons Clinical TMS Funding NIH CNDD-P20.

Dr. Onyinye Iweala has to disclose.

1. NIH NIAID K08 AI141691-01A1 NCE
2. EPITOPE (PI: Kim), Co-PI, DBV Technologies
3. NIH NIAID 1 R21 AI 154064 - 01 (PI: Smith)
4. 2020 AAAAI Foundation Career Development Award
5. P30 DK034987 (PI: Sandler), 2023 CGIBD Pilot/Feasibility Grant
6. 5UM2AI130836 (PI: Wood/Kim), collaborator
7. Telios Pharma Phase 2 Clinical Trial TL-895-201 (PI: Iweala)